Image

Medtronic has launched its new generation Enlite sensor, designed to provide a more consistent and comfortable experience for people using continuous glucose monitoring (CGM) in Europe.

The new generation Enlite sensor is the latest iteration of Medtronic’s Enlite glucose sensor and provides improved comfort and sensing experience.

It is used as part of the MiniMed Veo system, an integrated insulin pump and CGM system.

MiniMed Paradigm Veo system is used in conjunction with the Medtronic insulin pump. The device features a glucose sensor, MiniLink transmitter, and the Paradigm Veo insulin pump.

With its low glucose suspend function, MiniMed Veo system will actively protect the patient against the risk of hypoglycaemia even when sleeping.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

The low glucose suspend function stops insulin delivery for two hours if the patient does not respond to a low glucose warning.

"Sensors that perform well and are comfortable for people with diabetes to wear are critical to helping people achieve the clinical outcomes that CGM-enabled features like LGS provides."

MiniMed Veo system is clinically proven to provide better glucose control than multiple daily injections.

Improvements in the new generation Enlite include boosted sensor-to-transmitter connection, 80% reduction in implanted volume, updated sensor adhesive patch design to help reduce likelihood of skin irritation, and new chemistry pattern and layers that are designed for more consistent daily performance through the life of the sensor.

Medtronic vice-president Greg Meehan said the company is committed to developing technology that improves clinical outcomes for people living with diabetes.

"Sensors that perform well and are comfortable for people with diabetes to wear are critical to helping people achieve the clinical outcomes that CGM-enabled features like LGS provides," Meehan said. "New generation Enlite marks another critical milestone of innovation towards an artificial pancreas."

The company obtained CE Mark approval for the new generation Enlite. The device is currently available in six countries and will be launched across Western Europe within the next few months. However, it is not approved for use in the US.

Image: Medtronic’s MiniMed Paradigm system. Photo: courtesy of Me Three.